Munich-based startup Orbem, which develops AI-powered MRI technology for fast, non-invasive analysis of biological materials, has raised €55.5 million in a Series B financing round led by European deep tech investor Innovation Industries and joined by Supernova Invest as well as existing investors, as Vestbee was informed.
- Launched in Munich in 2019, Orbem develops AI-powered Magnetic Resonance Imaging (MRI) technology for the non-invasive analysis of biological materials.
- The system combines MRI sensors with AI to extract internal data from objects such as poultry eggs, fruits, nuts, and human tissue. In poultry, it can determine egg sex and fertilization status in under a second; in produce, it identifies internal defects and quality issues.
- Orbem began system development in 2020, installed its first Genus 1.0 system in 2021, and expanded into European markets by 2023.
- The firm has offices in Munich and Houston and employs more than 170 people across technical, operational, and scientific roles. The MRI platform generates actionable biological data at an industrial scale, forming a growing dataset used for applications in food production and health research.
Details of the deal
- The Series B round was led by Innovation Industries, joined by Supernova Invest, and supported by existing investors including General Catalyst, 83North, The Venture Collective, Possible Ventures, and several angel investors.
“Orbem is truly exceptional. Few companies manage to make such complex technology accessible and scalable across so many industries. With its platform, Orbem is already transforming entire sectors, and we are very pleased to join them on this journey," explains Pleuni Hooijman, Investment Manager at Innovation Industries.
- Orbem will use the €55.5 million funding to expand into the US market, scale its poultry solutions, enter the fruits and vegetables sector to reduce food waste, and invest in applying its AI-powered MRI insights to human healthcare.
“This new funding allows us to accelerate our US expansion and help more food producers and healthcare providers make better decisions with data. Our scalable platform and our rapidly growing, proprietary biological dataset are the perfect basis for achieving this. We are proud to see the trust our investors have placed in us and our vision to help the world see from the inside out," claims Dr. Pedro Gómez, co-founder and CEO of Orbem.
